Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia

JAMA Psychiatry

Volumn 70, Issue 5, 2013, Pages 481-489

  Roffman, Joshua L ^a   Lamberti, J Steven ^c   Achtyes, Eric ^d   Macklin, Eric A ^a   Galendez, Gail C ^a   Raeke, Lisa H ^a   Silverstein, Noah J ^a   Smoller, Jordan W ^a,b   Hill, Michele ^a   Goff, Donald C ^a,e,f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; PLACEBO;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CENTER; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEGATIVE SYNDROME; OUTPATIENT; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

EID: 84876925332     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.900     Document Type: Article

References (47)

1. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10(1):79-104. (Pubitemid 40139590)
2. Van Winkel R, Esquivel G, Kenis G, et al. REVIEW: genome-wide findings in schizophrenia and the role of gene-environment interplay. CNS Neurosci Ther. 2010;16(5):e185-e192.
3. Picker JD, Coyle JT. Do maternal folate and homocysteine levels play a role in neurodevelopmental processes that increase risk for schizophrenia? Harv Rev Psychiatry. 2005;13(4):197-205. (Pubitemid 41437571)
4. Susser E, Neugebauer R, Hoek HW, et al. Schizophrenia after prenatal famine: further evidence. Arch Gen Psychiatry. 1996;53(1):25-31.
5. St Clair D, Xu M, Wang P, et al. Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961. JAMA. 2005;294(5):557-562. (Pubitemid 41126897)
6. Brown AS, Bottiglieri T, Schaefer CA, et al. Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch Gen Psychiatry. 2007;64(1):31-39. (Pubitemid 46041736)
7. Herrán A, García-Unzueta MT, Amado JA, López- Cordovilla JJ, Díez-Manrique JF, Vázquez-Barquero JL. Folate levels in psychiatric outpatients. Psychiatry Clin Neurosci. 1999;53(4):531-533. (Pubitemid 29404178)
8. Koren G, Cohn T, Chitayat D, et al. Use of atypical antipsychotics during pregnancy and the risk of neural tube defects in infants. Am J Psychiatry. 2002;159(1):136-137. (Pubitemid 41070740)
9. Goff DC, Bottiglieri T, Arning E, et al. Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry. 2004;161(9):1705-1708. (Pubitemid 39201472)
10. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a commonmutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10(1):111-113.
11. Allen NC, Bagade S, McQueen MB, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet. 2008;40(7):827-834. (Pubitemid 351913655)
12. Roffman JL, Brohawn DG, Nitenson AZ, Macklin EA, Smoller JW, Goff DC. Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia [published online October 20, 2011]. Schizophr Bull. doi:10.1093/schbul/sbr150.
13. Godfrey PS, Toone BK, Carney MW, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990;336(8712):392-395. (Pubitemid 20252436)
14. Levine J, Stahl Z, Sela BA, et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry. 2006;60(3):265-269. (Pubitemid 44093437)
15. Rader JI. Folic acid fortification, folate status and plasma homocysteine. J Nutr. 2002;132(8)(suppl):2466S-2470S. (Pubitemid 34848128)
16. Hill M, Shannahan K, Jasinski S, et al. Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res. 2011;127(1-3):41-45.
17. Tucker KL, Mahnken B, Wilson PW, Jacques P, Selhub J. Folic acid fortification of the food supply: potential benefits and risks for the elderly population. JAMA. 1996;276(23):1879-1885. (Pubitemid 26419184)
18. Fava M, Mischoulon D. Folate in depression: efficacy, safety, differences in formulations, and clinical issues. J Clin Psychiatry. 2009;70(suppl 5):12-17.
19. Harnack L, Stevens M, Van Heel N, Schakel S, Dwyer JT, Himes J. A computer-based approach for assessing dietary supplement use in conjunction with dietary recalls. J Food Compost Anal. 2008;21(suppl 1):S78-S82. (Pubitemid 350011909)
20. Sharp L, Little J. Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am J Epidemiol. 2004;159(5):423-443. (Pubitemid 38280289)
21. Tunbridge EM, Harrison PJ, Warden DR, Johnston C, Refsum H, Smith AD. Polymorphisms in the catechol-O-methyltransferase (COMT) gene influence plasma total homocysteine levels. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(6):996-999.
22. Friso S, Choi SW, Girelli D, et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci U S A. 2002;99(8):5606-5611. (Pubitemid 34411596)
23. Obeid R, Kostopoulos P, Knapp JP, et al. Biomarkers of folate and vitamin B12 are related in blood and cerebrospinal fluid. Clin Chem. 2007;53(2):326-333. (Pubitemid 46338278)
24. Serot JM, Christmann D, Dubost T, Béne MC, Faure GC. CSF-folate levels are decreased in late-onset AD patients. J Neural Transm. 2001;108(1):93-99. (Pubitemid 32692616)
25. Halsted CH, Wong DH, Peerson JM, et al. Relations of glutamate carboxypeptidase II (GCPII) polymorphisms to folate and homocysteine concentrations and to scores of cognition, anxiety, and depression in a homogeneous Norwegian population: the Hordaland Homocysteine Study. Am J Clin Nutr. 2007;86(2):514-521. (Pubitemid 47256940)
26. Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry. 1995;34(13):4202-4210.
27. Halsted CH. The intestinal absorption of dietary folates in health and disease. J Am Coll Nutr. 1989;8(6):650-658.
28. Roffman JL, Weiss AP, Purcell S, et al. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry. 2008;63(1):42-48. (Pubitemid 350234878)
29. Wollack JB, Makori B, Ahlawat S, et al. Characterization of folate uptake by choroid plexus epithelial cells in a rat primary culture model. J Neurochem. 2008;104(6):1494-1503. (Pubitemid 351316763)
30. Alperin JB, Haggard ME. Cerebrospinal fluid folate (CFA) and the blood brain barrier. Clin Res. 1970;18:40.
31. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry. 1996;153(2):151-162. (Pubitemid 26038955)
32. Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007;164(10):1593-1602. (Pubitemid 350069740)
33. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214- 219.
34. Hermes ED, Sokoloff D, Stroup TS, Rosenheck RA. Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). J Clin Psychiatry. 2012;73(4):526-532.
35. Stroup TS, Lieberman JA, McEvoy JP, et al CATIE Investigators. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163(4):611-622. (Pubitemid 44464570)
36. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291(5):565-575. (Pubitemid 38500310)
37. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet. 2005;365(9455):224-232. (Pubitemid 40138016)
38. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324(17):1149-1155.
39. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337(4):230-236. (Pubitemid 27310438)
40. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346(7):476-483. (Pubitemid 34441738)
41. Van Dam F, Van Gool WA. Hyperhomocysteinemia and Alzheimer's disease: a systematic review. Arch Gerontol Geriatr. 2009;48(3):425-430.
42. Bønaa KH, Njølstad I, Ueland PM, et al NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354(15):1578-1588.
43. Lonn E, Yusuf S, Arnold MJ, et al; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1567-1577.
44. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med. 2006;354(26):2764-2772. (Pubitemid 43974194)
45. Zhou YH, Tang JY, Wu MJ, et al. Effect of folic acid supplementation on cardiovascular outcomes: a systematic review and meta-analysis. PLoS One. 2011;6(9):e25142.
46. Armitage JM, Bowman L, Clarke RJ, et al Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA. 2010;303(24):2486-2494.
47. Aisen PS, Schneider LS, Sano M, et al Alzheimer Disease Cooperative Study. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008;300(15):1774-1783.